Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Cash from Operations (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Cash from Operations for 4 consecutive years, with 25584000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations rose 9.7% to 25584000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 112022000.0, a 0.11% change, with the full-year FY2024 number at 110135000.0, down 24.66% from a year prior.
  • Cash from Operations was 25584000.0 for Q3 2025 at Century Therapeutics, up from 27592000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 86753000.0 in Q1 2022 to a low of 34623000.0 in Q1 2025.
  • A 4-year average of 18148666.67 and a median of 25584000.0 in 2025 define the central range for Cash from Operations.
  • Biggest YoY gain for Cash from Operations was 43.69% in 2023; the steepest drop was 133.68% in 2023.
  • Century Therapeutics' Cash from Operations stood at 22907000.0 in 2022, then decreased by 14.51% to 26230000.0 in 2023, then rose by 7.65% to 24223000.0 in 2024, then dropped by 5.62% to 25584000.0 in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Cash from Operations are 25584000.0 (Q3 2025), 27592000.0 (Q2 2025), and 34623000.0 (Q1 2025).